Screener
Roivant Sciences ROIV Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$2.13M+81.0% | $12.57M+542% | $8.34M+396% | -$5.69M-292% | -$11.21M-211% | ||
| -$189.84M+15.0% | —— | -$265.89M-257% | -$113.52M+50.7% | -$223.36M-334% | ||
| -$0.26+21.2% | —— | -$0.38-265% | -$0.17+45.2% | -$0.33-375% | ||
| -$365.39M-28.7% | —— | -$338.46M-24.7% | -$305.31M+9.4% | -$283.82M-192% | ||
| -$365.99M-28.5% | —— | -$339.15M-23.6% | -$306.23M+10.4% | -$284.92M-179% |
FAQ
- What is Roivant Sciences's revenue?
- Roivant Sciences (ROIV) generated $7.5M in revenue over the trailing twelve months, down 67.6% year over year.
- Is Roivant Sciences profitable?
- Roivant Sciences is not currently profitable: it reported a net loss of $792.6M over the trailing twelve months, a -6079.9% net margin.
- What is Roivant Sciences's earnings per share?
- Roivant Sciences's diluted EPS over the trailing twelve months is $-1.14.
- Where does Roivant Sciences's income statement data come from?
- Every line is extracted from Roivant Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
